Meeting ReportC3 glomerulopathy: consensus report
KEYWORDS
Cited by (0)
GBA is a consultant to Alexion Pharmaceuticals and Genentech and a Principal Investigator for an Alexion-funded research grant. FF has received fees from Alexion Pharmaceuticals for invited lectures and is member of an expert board supported by Alexion Pharmaceuticals. VF-B has received fees from Alexion Pharmaceuticals for invited lectures and is member of an expert board supported by Alexion Pharmaceuticals. VMH is a consultant to Alexion Pharmaceuticals, has received sponsored research from Taligen Therapeutics and Alexion, and has received licensing and royalty fees from Taligen and Alexion. SJ is a member of a scientific advisory board for Alexion Phamaceuticals. BPM is a consultant for Baxter International. CMN is a participant on the C3 Glomerulopathy Advisory Board, sponsored by Alexion Pharmaceuticals. DKP is a consultant for GlaxoSmithKline. MCP has received fees from Alexion Pharmaceuticals for invited lectures and funding for pre-clinical studies on experimental complement reagents. JMT is a paid consultant for Alexion Pharmaceuticals. CB, MD, GG, and PT are employees of Alexion Pharmaceuticals and own stock or stock options. SRdC has received fees from Alexion Pharmaceuticals for invited lectures and consultancy. CLH has an employment contract with GlaxoSmithKline. The remaining authors declared no competing interests.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/